Currently,
infections caused by drug-resistant bacteria have become
a new challenge in anti-infective treatment, seriously endangering
public health. In our continuous effort to develop new antimicrobials,
a series of novel honokiol/magnolol amphiphiles were prepared by mimicking
the chemical structures and antibacterial properties of cationic antimicrobial
peptides. Among them, compound 5i showed excellent antibacterial
activity against Gram-positive bacteria and clinical MRSA isolates
(minimum inhibitory concentrations (MICs) = 0.5–2 μg/mL)
with low hemolytic and cytotoxic activities and high membrane selectivity.
Moreover, 5i exhibited rapid bactericidal properties,
low resistance frequency, and good capabilities of disrupting bacterial
biofilms. Mechanism studies revealed that 5i destroyed
bacterial cell membranes, resulting in bacterial death. Additionally, 5i displayed high biosafety and potent in vivo anti-infective potency in a murine sepsis model. Our study indicates
that these honokiol/magnolol amphiphiles shed light on developing
novel antibacterial agents, and 5i is a potential antibacterial
candidate for combating MRSA infections.